CytRx publishes results from Arimoclomol Phase 2 trial for sIBM
Category: #health  By Saipriya Iyer  Date: 2020-02-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

CytRx publishes results from Arimoclomol Phase 2 trial for sIBM

CytRx Corporation, a biopharmaceutical firm that specializes principally in neurodegenerative and oncology diseases, recently announced its data from Orphazyme double-blinded Phase 2 study of arimoclomol for the treatment of sIBM (Sporadic Inclusion Body Myositis).

Reportedly, the study was a 24-patient randomized pilot (with 8 patients on placebo and 16 on arimoclomol) where almost 83% of patients receiving treatment from arimoclomol were stabilized whereas 25% managed to be stabilized in placebo.

Orphazyme trial is expected to be completed by the end of 2020, with interim analysis coming in the first half of 2020. Moreover, the results from this study are slated to be revealed by the first half of 2021, with regulatory submission being submitted by the second half of 2021.

Speaking on the move, Eric Curtis, President and Chief Operating Officer, CytRx, said that the company is with the findings of Phase 2 clinical study treating sIBM with arimoclomol. Moreover, it is projected that there are nearly 40,000 patients in Europe and the USA who go through this debilitating disease and presently there are no effective therapies for this massive population of sIBM patients.

Incidentally, CytRx has also announced that Orphazyme A/S licensed arimoclomol has completed a major new capital raise of around $110 million for expansion. Orphazyme claims that the funding will support the finalization of arimoclomol's clinical advancements in sIBM and help prepare regulatory filings in Europe and possibly in the U.S.

The investment also offers noteworthy cash for Orphazyme to further arimoclomol towards commercialization in NPC. Orphazyme also aims at using the proceeds to cover the completion of clinical development of arimoclomol in ALS.

Reports claim that CytRx is eligible to receive over $120 million in future milestones, along with royalties, from the company’s arimoclomol licensing deal. If received, the investment would secure a minimum of $250 million in net operating losses.

Source Credit: https://cytrxcorporation.gcs-web.com/news-releases/news-release-details/cytrx-corporation-highlights-recently-published-data-its?field_nir_news_date_value%5Bmin%5D=2017&items_per_page=10#views-exposed-form-widget-news-widget-news-ul



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

PharmaCyte to submit IND application to FDA for clinical trial in LAPC
PharmaCyte to submit IND application to FDA for clinical trial in LAPC
By Saipriya Iyer

PharmaCyte Biotech, a clinical-stage biotechnology company, is reportedly set to submit an IND (Investigational New Drug) application to the U.S. FDA. The IND application is related to the Phase 2b clinical trial among...

Immunic announces topline data from Phase 2 EMPhASIS, IMU-838 trial
Immunic announces topline data from Phase 2 EMPhASIS, IMU-838 trial
By Saipriya Iyer

Immunic, Inc. has recently announced positive topline results from the Phase 2 EMPhASIS trial of IMU-838, in patients with RRMS (relapsing-remitting multiple sclerosis). IMU-838 is a next-generation, orally available s...

Ciox announces acquisition of biomed-NLP technology company, Medal
Ciox announces acquisition of biomed-NLP technology company, Medal
By Saipriya Iyer

Ciox Health has recently announced the acquisition of Medal, Inc., a biomed-NLP (biomedical Natural Language Processing) technology company based in San Francisco. Medal is also a leader in integrating AI techniques fo...